Reduced O
nicotinamide B
adenine I
dinucleotide I
phosphate I
- O
diaphorase O
( O
NADPH B
- O
d O
) O
histochemistry O
was O
also O
employed O
to O
visualize O
NOS O
as O
an O
index O
of O
enzyme O
expression O
in O
mice O
brain O
regions O
related O
to O
motor O
control O
. O

Intracerebroventricular O
injection O
of O
ethacrynic B
acid I
( O
50 O
% O
convulsive O
dose O
; O
50 O
micrograms O
/ O
mouse O
) O
accelerated O
the O
synthesis O
/ O
turnover O
of O
5 B
- I
hydroxytryptamine I
( O
5 B
- I
HT I
) O
but O
suppressed O
the O
synthesis O
of O
gamma B
- I
aminobutyric I
acid I
and O
acetylcholine B
in O
mouse O
brain O
. O

Pharmacology O
of O
gamma B
- I
aminobutyric I
acidA I
receptor O
complex O
after O
the O
in O
vivo O
administration O
of O
the O
anxioselective O
and O
anticonvulsant O
beta B
- I
carboline I
derivative O
abecarnil B
. O

In O
rodents O
, O
the O
effect O
of O
the O
beta B
- I
carboline I
derivative O
isopropyl B
- I
6 I
- I
benzyloxy I
- I
4 I
- I
methoxymethyl I
- I
beta I
- I
carboline I
- I
3 I
- I
carboxylate I
( O
abecarrnil B
) O
, O
a O
new O
ligand O
for O
benzodiazepine B
receptors O
possessing O
anxiolytic O
and O
anticonvulsant O
properties O
, O
was O
evaluated O
on O
the O
function O
of O
central O
gamma B
- I
aminobutyric I
acid I
( O
GABA B
) O
A O
receptor O
complex O
, O
both O
in O
vitro O
and O
in O
vivo O
. O

Added O
in O
vitro O
to O
rat O
cortical O
membrane O
preparation O
, O
abecarnil B
increased O
[ O
3H O
] O
GABA B
binding O
, O
enhanced O
muscimol B
- O
stimulated O
36Cl O
- O
uptake O
and O
reduced O
the O
binding O
of O
t B
- I
[ I
35S I
] I
butylbicyclophosphorothionate I
( O
[ B
35S I
] I
TBPS I
) O
. O

These O
effects O
were O
similar O
to O
those O
induced O
by O
diazepam B
, O
whereas O
the O
partial O
agonist O
Ro B
16 I
- I
6028 I
( O
tert B
- I
butyl I
- I
( I
S I
) I
- I
8 I
- I
bromo I
- I
11 I
, I
12 I
, I
13 I
, I
13a I
- I
tetrahydro I
- I
9 I
- I
oxo I
- I
9H I
- I
imidazo I
[ I
1 I
, I
5 I
- I
a I
] I
- I
pyrrolo I
- I
[ I
2 I
, I
1 I
- I
c I
] I
[ I
1 I
, I
4 I
] I
benzodiazepine I
- I
1 I
- I
carboxylate I
) O
showed O
very O
weak O
efficacy O
in O
these O
biochemical O
tests O
. O

After O
i O
. O
p O
. O
injection O
to O
rats O
, O
abecarnil B
and O
diazepam B
decreased O
in O
a O
time O
- O
dependent O
and O
dose O
- O
related O
( O
0 O
. O
25 O
- O
20 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
manner O
[ B
35S I
] I
TBPS I
binding O
measured O
ex O
vivo O
in O
the O
cerebral O
cortex O
. O

Moreover O
, O
both O
drugs O
at O
the O
dose O
of O
0 O
. O
5 O
mg O
/ O
kg O
antagonized O
completely O
the O
convulsant O
activity O
and O
the O
increase O
of O
[ B
35S I
] I
TBPS I
binding O
induced O
by O
isoniazide B
( O
350 O
mg O
/ O
kg O
s O
. O
c O
. O
) O
as O
well O
as O
the O
increase O
of O
[ B
35S I
] I
TBPS I
binding O
induced O
by O
foot O
- O
shock O
stress O
. O

Moreover O
, O
both O
drugs O
at O
the O
dose O
of O
0 O
. O
5 O
mg O
/ O
kg O
antagonized O
completely O
the O
convulsant O
activity O
and O
the O
increase O
of O
[ B
35S I
] I
TBPS I
binding O
induced O
by O
isoniazide B
( O
350 O
mg O
/ O
kg O
s O
. O
c O
. O
) O
as O
well O
as O
the O
increase O
of O
[ B
35S I
] I
TBPS I
binding O
induced O
by O
foot O
- O
shock O
stress O
. O

To O
better O
correlate O
the O
biochemical O
and O
the O
pharmacological O
effects O
, O
we O
studied O
the O
action O
of O
abecarnil B
on O
[ B
35S I
] I
TBPS I
binding O
, O
exploratory O
motility O
and O
on O
isoniazid B
- O
induced O
biochemical O
and O
pharmacological O
effects O
in O
mice O
. O

Moreover O
, O
0 O
. O
05 O
mg O
/ O
kg O
of O
this O
beta B
- I
carboline I
reduced O
markedly O
the O
increase O
of O
[ B
35S I
] I
TBPS I
binding O
and O
the O
convulsions O
induced O
by O
isoniazid B
( O
200 O
mg O
/ O
kg O
s O
. O
c O
. O
) O
. O
( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

T B
. I
chebula I
extract I
pretreatment O
was O
found O
to O
ameliorate O
the O
effect O
of O
isoproterenol B
on O
lipid O
peroxide B
formation O
and O
retained O
the O
activities O
of O
the O
diagnostic O
marker O
enzymes O
. O

Anticonvulsant O
effect O
of O
eslicarbazepine B
acetate I
( O
BIA B
2 I
- I
093 I
) O
on O
seizures O
induced O
by O
microperfusion O
of O
picrotoxin B
in O
the O
hippocampus O
of O
freely O
moving O
rats O
. O

Eslicarbazepine B
acetate I
( O
BIA B
2 I
- I
093 I
, O
S B
- I
( I
- I
) I
- I
10 I
- I
acetoxy I
- I
10 I
, I
11 I
- I
dihydro I
- I
5H I
- I
dibenzo I
/ I
b I
, I
f I
/ I
azepine I
- I
5 I
- I
carboxamide I
) O
is O
a O
novel O
antiepileptic O
drug O
, O
now O
in O
Phase O
III O
clinical O
trials O
, O
designed O
with O
the O
aim O
of O
improving O
efficacy O
and O
safety O
in O
comparison O
with O
the O
structurally O
related O
drugs O
carbamazepine B
( O
CBZ B
) O
and O
oxcarbazepine B
( O
OXC B
) O
. O

Risks O
and O
benefits O
of O
COX B
- I
2 I
inhibitors I
vs O
non O
- O
selective O
NSAIDs O
: O
does O
their O
cardiovascular O
risk O
exceed O
their O
gastrointestinal O
benefit O
? O

OBJECTIVES O
: O
The O
risk O
of O
acute O
myocardial O
infarction O
( O
AMI O
) O
with O
COX B
- I
2 I
inhibitors I
may O
offset O
their O
gastrointestinal O
( O
GI O
) O
benefit O
compared O
with O
non O
- O
selective O
( O
NS O
) O
non B
- I
steroidal I
anti I
- I
inflammatory I
drugs I
( O
NSAIDs O
) O
. O

We O
aimed O
to O
compare O
the O
risks O
of O
hospitalization O
for O
AMI O
and O
GI O
bleeding O
among O
elderly O
patients O
using O
COX B
- I
2 I
inhibitors I
, O
NS O
- O
NSAIDs O
and O
acetaminophen B
. O

Vincristine B
, O
dexamethasone B
, O
and O
polyethylene B
glycol I
- I
asparaginase I
were O
also O
administered O
before O
the O
episode O
as O
part O
of O
induction O
therapy O
. O

Anti B
- I
thyroid I
drugs I
, O
like O
carbimazole B
and O
propylthiouracil B
( O
PTU B
) O
are O
commonly O
prescribed O
for O
the O
treatment O
of O
hyperthyroidism O
. O

Hepatic O
tissue O
was O
assayed O
for O
lipid O
peroxidation O
products O
and O
oxidized B
and I
reduced I
glutathione I
. O

On O
the O
other O
hand O
, O
induction O
of O
metallothionein B
( O
MT B
) O
by O
ZnSO B
( I
4 I
) I
and O
its O
role O
in O
neuroprotection O
has O
been O
documented O
. O

The O
second O
group O
administered O
ZnSO B
( I
4 I
) I
( O
0 O
. O
1 O
micromol O
/ O
10 O
microl O
normal O
saline O
, O
i O
. O
c O
. O
v O
, O
once O
) O
then O
BCNU B
solvent O
( O
i O
. O
v O
) O
after O
24 O
h O
. O

Fourth O
group O
received O
a O
single O
dose O
of O
ZnSO B
( I
4 I
) I
( O
0 O
. O
1 O
micromol O
/ O
10 O
microl O
normal O
saline O
, O
i O
. O
c O
. O
v O
) O
then O
BCNU B
( O
20 O
mg O
/ O
kg O
, O
i O
. O
v O
, O
once O
) O
after O
24 O
h O
. O

ZnSO B
( I
4 I
) I
pretreatment O
counteracted O
BCNU B
- O
induced O
inhibition O
of O
GR O
and O
depletion O
of O
GSH B
and O
resulted O
in O
significant O
reduction O
in O
the O
levels O
of O
MDA B
and O
TNFalpha O
as O
well O
as O
the O
activity O
of O
caspase O
- O
3 O
. O

The O
histological O
features O
were O
improved O
in O
hippocampus O
of O
rats O
treated O
with O
ZnSO B
( I
4 I
) I
+ O
BCNU B
compared O
to O
only O
BCNU B
- O
treated O
animals O
. O

This O
side O
effect O
of O
IFO B
raises O
the O
requirement O
for O
the O
co O
- O
administration O
with O
sodium B
2 I
- I
sulfanylethanesulfonate I
( O
Mesna B
) O
aiming O
to O
avoid O
or O
minimize O
this O
effect O
. O

Its O
mechanism O
of O
action O
is O
not O
well O
understood O
although O
it O
has O
been O
proposed O
that O
lindane B
acts O
as O
a O
non O
- O
competitive O
antagonist O
at O
the O
gamma B
- I
aminobutyric I
acid I
( O
GABA B
) O
- O
A O
receptor O
. O

Furthermore O
, O
reduction O
of O
ER O
stress O
in O
the O
TM O
with O
sodium B
4 I
- I
phenylbutyrate I
prevented O
dexamethasone B
- O
induced O
ocular O
hypertension O
in O
WT O
mice O
. O

However O
, O
the O
Rg1 B
and I
Rb1 I
ginsenosides I
failed O
to O
prevent O
OIH O
in O
either O
test O
. O

The O
present O
study O
aimed O
to O
evaluate O
the O
GFC B
effects O
at O
doses O
of O
25 O
, O
50 O
or O
75 O
mg O
/ O
kg O
on O
seizure O
parameters O
to O
determine O
their O
anticonvulsant O
activity O
and O
its O
effects O
on O
amino B
acid I
( O
r B
- I
aminobutyric I
acid I
( O
GABA B
) O
, O
glutamine B
, O
aspartate B
and O
glutathione B
) O
levels O
as O
well O
as O
on O
acetylcholinesterase O
( O
AChE O
) O
activity O
in O
mice O
hippocampus O
after O
seizures O
. O

Renal O
function O
was O
assessed O
by O
biochemical O
( O
plasma O
urea B
and O
creatinine B
) O
, O
functional O
( O
urine O
analysis O
and O
[ O
3H O
] O
inulin O
and O
[ O
14C O
] O
p B
- I
aminohippuric I
acid I
clearances O
) O
and O
morphological O
( O
degree O
of O
necrosis O
) O
indices O
. O

Increasing O
recognition O
of O
the O
importance O
of O
calcium B
in O
the O
pathogenesis O
of O
cardiovascular O
disease O
has O
stimulated O
research O
into O
the O
use O
of O
calcium B
channel I
blocking I
agents I
for O
treatment O
of O
a O
variety O
of O
cardiovascular O
diseases O
. O

In O
the O
present O
study O
, O
the O
effects O
of O
manipulating O
the O
activity O
of O
the O
gamma B
- I
aminobutyric I
acid I
( O
GABA B
) O
- O
mediated O
synaptic O
inhibition O
within O
the O
substantia O
nigra O
on O
seizures O
produced O
by O
pilocarpine B
in O
rats O
, O
were O
investigated O
. O

In O
animals O
pretreated O
with O
microinjections O
of O
isoniazid B
, O
150 O
micrograms O
, O
an O
inhibitor O
of O
activity O
of O
the O
GABA B
- O
synthesizing O
enzyme O
, O
L B
- I
glutamic I
acid I
decarboxylase O
, O
into O
the O
substantia O
nigra O
pars O
reticulata O
( O
SNR O
) O
, O
bilaterally O
, O
non O
- O
convulsant O
doses O
of O
pilocarpine B
, O
100 O
and O
200 O
mg O
/ O
kg O
, O
resulted O
in O
severe O
motor O
limbic O
seizures O
and O
status O
epilepticus O
. O

The O
effects O
of O
serial O
treatment O
with O
doxorubicin B
on O
dynamic O
myocardial O
scintigraphy O
with O
[ B
omega I
- I
I I
- I
131 I
] I
heptadecanoic I
acid I
( O
I B
- I
131 I
HA I
) O
, O
and O
on O
global O
left O
- O
ventricular O
function O
determined O
echocardiographically O
, O
were O
studied O
in O
a O
group O
of O
nine O
mongrel O
dogs O
. O

A O
significant O
increase O
in O
the O
myocardial O
t1 O
/ O
2 O
of O
the O
I B
- I
131 I
HA I
was O
observed O
only O
at O
a O
higher O
cumulative O
dose O
, O
10 O
mg O
/ O
kg O
. O

Our O
findings O
suggest O
that O
the O
changes O
leading O
to O
an O
alteration O
of O
myocardial O
dynamic O
imaging O
with O
I B
- I
131 I
HA I
are O
not O
the O
initiating O
factor O
in O
doxorubicin B
cardiotoxicity O
. O

Lamivudine B
is O
effective O
in O
suppressing O
hepatitis O
B O
virus O
DNA O
in O
Chinese O
hepatitis B
B I
surface I
antigen I
carriers O
: O
a O
placebo O
- O
controlled O
trial O
. O

We O
performed O
a O
single O
- O
blind O
, O
placebo O
- O
controlled O
study O
to O
assess O
its O
effectiveness O
and O
safety O
in O
Chinese O
hepatitis B
B I
surface I
antigen I
( O
HBsAg B
) O
carriers O
. O

There O
was O
no O
change O
in O
the O
levels O
of O
DA B
, O
norepinephrine B
( O
NE B
) O
, O
serotonin B
( O
5 B
- I
HT I
) O
, O
or O
their O
metabolites O
in O
the O
arcuate O
nucleus O
( O
AN O
) O
, O
medial O
preoptic O
area O
( O
MPA O
) O
, O
caudate O
putamen O
( O
CP O
) O
, O
substantia O
nigra O
( O
SN O
) O
, O
and O
zona O
incerta O
( O
ZI O
) O
, O
except O
for O
a O
decrease O
in O
5 B
- I
hydroxyindoleacetic I
acid I
( O
5 B
- I
HIAA I
) O
in O
the O
AN O
after O
6 O
- O
months O
of O
hyperprolactinemia O
and O
an O
increase O

A O
relative O
gamma B
- I
aminobutyric I
acid I
- O
ergic O
deficiency O
might O
occur O
because O
diazepam B
, O
a O
gamma B
- I
aminobutyric I
acid I
- O
mimetic O
agent O
, O
was O
strikingly O
effective O
. O

A O
relative O
gamma B
- I
aminobutyric I
acid I
- O
ergic O
deficiency O
might O
occur O
because O
diazepam B
, O
a O
gamma B
- I
aminobutyric I
acid I
- O
mimetic O
agent O
, O
was O
strikingly O
effective O
. O

